Mogling Bio
Cdc42 inhibition, CASIN, stem cell rejuvenation
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
Cdc42 inhibition, CASIN, stem cell rejuvenation
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Mogling Bio Cdc42 inhibition, CASIN, stem cell rejuvenation
Mogling Bio is developing pharmacological approaches to restore function in aged and exhausted cells, particularly stem cells. Its platform targets age-associated overactivation of Cdc42, aiming to rejuvenate stem cell function and address tissue degeneration and age-related disease. The company describes applications across osteoporosis, immune dysfunction, blood disorders and neurodegeneration.
The published score reflects a curated read of public evidence across 16 dimensions. Each dimension below shows the rationale we used. Disagree with a reading? Tell us where we are wrong →
Higher up = higher Eternal Search score. Further right = closer to achieving real longevity outcomes (early mechanism → translational → near-term readout). Bubble size = capital deployed. Watch for MISMATCHES: big bubbles on the left are well-capitalized but far from goals; small bubbles on the right are doing more with less.
Mogling Bio — Early mechanism · Lower middle. Derived deterministically from 25 extracted project(s). Most-advanced status: preclinical. Band: early_mechanism. Modifiers: +5 depth (21 programs at preclinical).…
Source: Deterministic